Moreover, CYM‐5478 also reduced the maximum AAA diameter and improved the survival rate of CaCl2‐induced AAA model mice, reduced the levels of MMP2 and MMP9 (Figure 7G‐K) and increased the levels of α‐SMA, Calponin1 and SM‐MHC compared with saline treatment in the CaCl2 group (Figure 7L). Here, MMP9 is linked to triple-A syndrome.